Ceritinib

4 trials 1 recruiting LOncology

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

4 Sponsors

7 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 2 Phase IV: 1

Oversight events:

2 urgent safety measures across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 2

Sponsors using this IMP

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Institut National De La Sante Et De La Recherche Medicale 1 Novartis Pharma AG 1 Oslo University Hospital HF 1

All trials

4 total

Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A study for patients who have completed a prior global Novartis sponsored ceritinib (LDK378) study and are judged by the investigator to ben… Ended

2024-511040-58-00 Phase IV 6 countries Novartis Pharma AG
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended

2024-514873-22-00 Phase III 1 country Institut National De La Sante Et De La Recherche Medicale

Showing 1–4 of 4 trials

← All drugs A–Z